Keratitis due to Aspergillus flavus successfully treated with thiabendazole.

Upadhyay, Madan Prasad; West, E P; Sharma, Ajay

doi:10.1136/bjo.64.1.30

Cited by 13 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, griseofulvin has no antifungal activity against Candida spp., as the fungus does not uptake the compound into the fungal cell, and therefore it would not be expected to be identified [22] . The compound thiabendazole is used agriculturally as a fungicide and has been used clinically in treatment of Aspergillus flavus [23] , [24] , however it is also nematocidial [25] . Several other antinematode compounds were represented in the chemical library including the clinically relevant agent albendazole and the avermectin, abamectin.…”

Section: Resultsmentioning

confidence: 99%

Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay

et al. 2009

View full text Add to dashboard Cite

Candida albicans, the most common human pathogenic fungus, can establish a persistent lethal infection in the intestine of the microscopic nematode Caenorhabditis elegans. The C. elegans–C. albicans infection model was previously adapted to screen for antifungal compounds. Modifications to this screen have been made to facilitate a high-throughput assay including co-inoculation of nematodes with C. albicans and instrumentation allowing precise dispensing of worms into assay wells, eliminating two labor-intensive steps. This high-throughput method was utilized to screen a library of 3,228 compounds represented by 1,948 bioactive compounds and 1,280 small molecules derived via diversity-oriented synthesis. Nineteen compounds were identified that conferred an increase in C. elegans survival, including most known antifungal compounds within the chemical library. In addition to seven clinically used antifungal compounds, twelve compounds were identified which are not primarily used as antifungal agents, including three immunosuppressive drugs. This assay also allowed the assessment of the relative minimal inhibitory concentration, the effective concentration in vivo, and the toxicity of the compound in a single assay.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay

et al. 2009

View full text Add to dashboard Cite

show abstract

“…[24, 5T 54], Thiobendazole has been used in a 4% suspension both against Fusarium spp. [24] and Aspergillus flavus [55]. In a prospective, randomized crossover trial, 1% silver sul phadiazine was compared with 1% miconazole drops in 40 patients with keratomycosis [56].…”

Section: Azolesmentioning

confidence: 99%

Topical Antimycotics in Ophthalmology

Behrens–Baumann¹

1997

Ophthalmologica

View full text Add to dashboard Cite

This article surveys the current treatment of fungal eye diseases with topical antimycotics. Their various pharmacokinetic characteristics and antimycotic activities are presented and, in addition, the clinical symptoms of fungal eye diseases which can be topically treated are described, so that a correct diagnosis can be achieved rapidly to avoid delaying proper therapy. Finally, guidelines for treatment of keratomycosis are recommended.

show abstract

“…In livestock, thiabendazole is applied as an antihelmintic (PubChem SID: 24900571). Thiabendazole, 2-(4′-thiazolyl) benzimidazole, was first described in 1961 as a broad spectrum antihelmintic [ 1 ]; it has been used as a topical treatment against human skin diseases caused by fungi, such as dermatophytosis [ 2 , 3 ] and chromomycosis [ 4 , 5 ], and there is also a case report of keratitis due to Aspergillus flavus successfully treated with TBZ [ 6 ]; it has low acute toxicity (category III) and is neither irritating to the eyes or skin nor is a dermal sensitizer [ 7 ]. Although TBZ has been tested against dermatophytes before [ 8 , 9 ], we could not find any reports where TBZ was submitted to susceptibility testing using the Clinical and Laboratory Standards Institute's protocol M38-A2.…”

Section: Introductionmentioning

confidence: 99%

Susceptibility of Dermatophytes to Thiabendazole Using CLSI Broth Macrodilution

2012

View full text Add to dashboard Cite

Objective. To evaluate in vitro antifungal activity of thiabendazole against strains of dermatophytes using a reference method for filamentous fungi. Materials and Methods. Dermatophytes' susceptibility to thiabendazole (TBZ) and fluconazole (FCZ) was evaluated using macrodilution method of protocol M38-A2 of the Clinical and Laboratory Standards Institute (CLSI). Results. MIC ranges of TBZ for all strains were narrower and/or smaller than those of FCZ. TBZ showed a significantly greater potency than FCZ (P = 0.05) against all isolates. Discussion. Although there have been approaches to evaluate the antifungal activity of TBZ in human mycoses, no tests had been made with a standardized protocol. Susceptibility data resulted from this study shows that although TBZ is not a particularly strong inhibitor of dermatophytes, it displays a stable and constant effect against all isolates tested. Conclusion. Results show that TBZ is more effective against strains of dermatophytes than FCZ. We acknowledge the antifungal effect of TBZ against dermatophyte isolates.

show abstract

Keratitis due to Aspergillus flavus successfully treated with thiabendazole.

Cited by 13 publications

References 6 publications

Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay

Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay

Topical Antimycotics in Ophthalmology

Susceptibility of Dermatophytes to Thiabendazole Using CLSI Broth Macrodilution

Contact Info

Product

Resources

About